Wordt geladen...
Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors
PURPOSE: Following promising responses to the DNA methyltransferase (DNMT) inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) combined with tetrahydrouridine (THU) in phase 1 testing, we initiated a non-randomized phase 2 study to assess response to this combination in patients with advanced solid tumor ty...
Bewaard in:
| Gepubliceerd in: | Cancer Chemother Pharmacol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer Berlin Heidelberg
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7188725/ https://ncbi.nlm.nih.gov/pubmed/32314030 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04073-5 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|